Cabaletta Bio, Inc.
CABA
$3.51
-$0.12-3.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -22.25% | 0.12% | 20.67% | 33.59% | 43.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.12% | 40.98% | 51.61% | 32.48% | 45.96% |
| Operating Income | -26.12% | -40.98% | -51.61% | -32.48% | -45.96% |
| Income Before Tax | -28.64% | -46.48% | -63.50% | -43.50% | -56.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.64% | -46.48% | -63.50% | -43.50% | -56.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.64% | -46.48% | -63.50% | -43.50% | -56.02% |
| EBIT | -26.12% | -40.98% | -51.61% | -32.48% | -45.96% |
| EBITDA | -26.85% | -41.75% | -52.21% | -32.61% | -46.06% |
| EPS Basic | 38.46% | 29.14% | -30.65% | -39.43% | -41.30% |
| Normalized Basic EPS | 38.47% | 29.15% | -30.64% | -39.43% | -41.32% |
| EPS Diluted | 38.46% | 29.24% | -30.23% | -38.88% | -41.30% |
| Normalized Diluted EPS | 38.47% | 29.15% | -30.64% | -39.43% | -41.32% |
| Average Basic Shares Outstanding | 109.04% | 106.71% | 25.14% | 2.92% | 10.41% |
| Average Diluted Shares Outstanding | 109.04% | 106.71% | 25.14% | 2.92% | 10.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |